dihexa
Dihexa, explained.
Dihexa is one of the most discussed names among experimental cognitive peptides — a synthetic, brain-targeting molecule that has drawn research interest for its effect on synapse formation in animal studies. This page is a neutral overview of what dihexa is, how it is thought to work, and where its regulatory status stands.
Educational only — not medical advice.
Dihexa (developmental code PNB-0408) is a synthetic oligopeptide derived from angiotensin IV, engineered to cross the blood-brain barrier and survive oral administration. In rodent studies it has been reported as a potent driver of synapse formation, which is the basis for research interest in it as a cognitive compound. It has no human trials, is not FDA-approved, and is sold only as a research chemical.
What dihexa is
Dihexa is a small synthetic peptide — an oligopeptide built around the sequence Hexanoyl-Tyr-Ile-Ahx-NH2 — that grew out of research on angiotensin IV, a fragment of the body's renin-angiotensin system that has been tied to memory. Chemists at Washington State University took that lead and reworked it: they capped one end with a fatty hexanoyl group and the other with a 6-aminohexanoic amide, deliberately making the molecule lipophilic. Those changes give dihexa two unusual traits for a peptide — it is designed to cross the blood-brain barrier, and it is stable enough to be administered orally, where most peptides simply break down. It also carries the developmental code PNB-0408. Important to keep in view: dihexa is preclinical. It has never been through a human clinical trial, it is not approved by the FDA or any regulator, and everything sold under its name today is an unapproved research chemical.
How dihexa is thought to work
The headline mechanism proposed for dihexa is synaptogenesis — the formation of new connections between neurons. In lab dishes and in rodents it has been reported to trigger the formation of dendritic spines and synapses in the hippocampus, the brain's memory hub, and to do so with striking potency relative to its parent angiotensin IV molecule. The leading explanation for how it does this was that dihexa engages hepatocyte growth factor (HGF) and amplifies signaling through HGF's receptor, c-Met. That HGF/c-Met story is now contested: the foundational paper describing it was retracted in April 2025, so the mechanism should be treated as unconfirmed rather than settled. There is also a background thread tying dihexa back to angiotensin IV's interaction with insulin-regulated aminopeptidase (IRAP), though how much that contributes is unresolved. In short, the synaptogenesis observations are preclinical findings, but the molecular 'why' behind them is genuinely open.
Areas of research interest
- Memory and learning — the central area of study, based on rodent experiments examining chemically-induced memory deficits
- Synaptogenesis — its most-studied property in the lab: formation of new dendritic spines and synapses
- Neurodegeneration research — the original target application, including Alzheimer's-style models in animals
- General cognition — a topic of discussion in the nootropic community, where any human data is purely anecdotal
- Oral brain-targeting design — scientific interest in a peptide engineered to be administered orally and reach the brain, unlike most
Safety & legal status
The central safety fact about dihexa is that no human safety data exists; rodent studies reported no obvious liver, kidney, or behavioral toxicity, but they were not designed as toxicology studies. A specific concern noted in the literature is that the HGF/c-Met pathway dihexa is thought to target is a known pro-cancer pathway, so the safety picture carries a real theoretical oncogenic question, and the 2025 retraction of the key mechanism paper only deepens the uncertainty. As a research chemical, identity and purity are not guaranteed from vendor to vendor. Legally, dihexa is not FDA-approved and is not approved by any regulator worldwide; as of 2026-06-05 it is not on the FDA's 503A bulk-substance lists, status varies by country, and it may be banned in tested sport. None of this is medical advice — consult a qualified licensed provider about your own situation.
Dihexa vs Semax & Selank
| Dihexa | Semax / Selank | |
|---|---|---|
| Evidence level | Preclinical only (rodent; no human trials) | Russian clinical use in humans |
| Origin | Synthetic, derived from angiotensin IV | Synthetic regulatory peptides (Russian development) |
| Primary research interest | Synaptogenesis / memory | Cognition, focus, and mood/anxiety |
| Mechanism confidence | Low — key HGF/c-Met paper retracted (2025) | Better characterized in their own research base |
| Unresolved safety questions | High — no human data, pro-cancer pathway concern | More established human track record |
| Approval status | Not approved anywhere; research-only | Not FDA-approved; clinical use in Russia |
How PepEasy helps
Learn it
Find neutral, evidence-graded reference material about dihexa — what it is, how synaptogenesis is thought to work, what the rodent studies actually showed, why the 2025 retraction matters, and how it compares to better-studied cognitive peptides like Semax and Selank.
Understand the science
PepEasy organizes neutral, sourced reference material so you can understand the research landscape around a compound — never as a recommendation to use it.
Frequently asked
What are dihexa's side effects?+
Honestly, they are largely unknown in humans because there is no human safety data. Rodent studies reported no obvious liver, kidney, or behavioral toxicity, but were not designed as toxicology studies. A flagged concern in the literature is that dihexa is thought to activate the HGF/c-Met pathway, which is associated with cancer — a serious unresolved theoretical question. This is not medical advice — consult a qualified licensed provider.
What does dihexa research show?+
In animal research, dihexa has been reported as a potent driver of synapse formation and has been studied in models of chemically-induced memory deficits, which is the basis for research interest in it as a cognitive compound. But these are preclinical (rodent) findings — there is no controlled human data, and any human cognitive discussion remains anecdotal. Treat the research as early and unproven.
Is dihexa a steroid?+
No, dihexa is not a steroid — it's a synthetic oligopeptide derived from angiotensin IV that is studied for its effect on synapse formation, not hormones. It cannot be called safe: there is no human safety data at all, and its proposed target pathway has cancer associations. It is sold only as a research chemical with no quality oversight. This is not medical advice — consult a qualified licensed provider.
Is dihexa FDA approved?+
No. Dihexa is not approved by the FDA or any regulator anywhere in the world, and it has never undergone a human clinical trial. As of 2026-06-05 it is not on the FDA's 503A bulk-substance lists either. It is sold strictly as a research chemical, and a related clinical drug (fosgonimeton) failed its 2024 Alzheimer's trial.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more